Perennial Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.09M | Sell |
19,702
-21,186
| -52% | -$3.18M | 0.48% | 60 |
|
|
2026
Q1 | $6.25M | Sell |
40,888
-1,456
| -3% | -$223K | 1.06% | 34 |
|
|
2025
Q4 | $5.84M | Buy |
42,344
+407
| +1% | +$53.3K | 0.98% | 36 |
|
|
2025
Q3 | $5.38M | Sell |
41,937
-8
| -0% | -$976 | 0.93% | 37 |
|
|
2025
Q2 | $5.08M | Sell |
41,945
-71
| -0.2% | -$8K | 0.94% | 37 |
|
|
2025
Q1 | $4.69M | Buy |
42,016
+845
| +2% | +$90K | 0.93% | 40 |
|
|
2024
Q4 | $4.01M | Buy |
+41,171
| New | +$4.39M | 0.87% | 41 |
|
|
2024
Q2 | $4.02M | Buy |
37,743
+2,069
| +6% | +$208K | 0.9% | 39 |
|
|
2024
Q1 | $3.45M | Sell |
35,674
-116
| -0.3% | -$11.9K | 0.8% | 45 |
|
|
2023
Q4 | $3.61M | Buy |
35,790
+711
| +2% | +$68.6K | 0.89% | 42 |
|
|
2023
Q3 | $3.57M | Buy |
35,079
+471
| +1% | +$47.8K | 0.96% | 39 |
|
|
2023
Q2 | $3.49M | Sell |
34,608
-740
| -2% | -$74K | 0.89% | 42 |
|
|
2023
Q1 | $3.25M | Buy |
35,348
+310
| +0.9% | +$27.1K | 0.93% | 40 |
|
|
2022
Q4 | $3.18M | Sell |
35,038
-487
| -1% | -$41K | 1.01% | 40 |
|
|
2022
Q3 | $2.7M | Buy |
35,525
+2,035
| +6% | +$169K | 0.89% | 44 |
|
|
2022
Q2 | $2.83M | Buy |
33,490
+1,372
| +4% | +$120K | 0.88% | 44 |
|
|
2022
Q1 | $2.82M | Sell |
32,118
-63
| -0.2% | -$5.46K | 0.75% | 48 |
|
|
2021
Q4 | $2.81M | Sell |
32,181
-2,059
| -6% | -$171K | 0.76% | 44 |
|
|
2021
Q3 | $2.8M | Buy |
34,240
+2,397
| +8% | +$216K | 0.82% | 44 |
|
|
2021
Q2 | $2.9M | Buy |
31,843
+1,278
| +4% | +$114K | 0.84% | 42 |
|
|
2021
Q1 | $2.61M | Buy |
30,565
+956
| +3% | +$85.8K | 0.82% | 42 |
|
|
2020
Q4 | $2.8M | Buy |
29,609
+748
| +3% | +$65.4K | 0.98% | 37 |
|
|
2020
Q3 | $2.51M | Buy |
28,861
+1,927
| +7% | +$167K | 1.03% | 37 |
|
|
2020
Q2 | $2.35M | Buy |
26,934
+4,690
| +21% | +$405K | 1% | 40 |
|
|
2020
Q1 | $1.83M | Buy |
22,244
+3,039
| +16% | +$271K | 1.02% | 37 |
|
|
2019
Q4 | $1.82M | Buy |
19,205
+49
| +0.3% | +$4.4K | 0.87% | 43 |
|
|
2019
Q3 | $1.67M | Buy |
19,156
+1,695
| +10% | +$152K | 0.86% | 43 |
|
|
2019
Q2 | $1.59M | Buy |
17,461
+384
| +2% | +$32.5K | 0.85% | 44 |
|
|
2019
Q1 | $1.47M | Buy |
17,077
+1,808
| +12% | +$145K | 0.84% | 47 |
|
|
2018
Q4 | $1.17M | Buy |
15,269
+1,657
| +12% | +$129K | 0.76% | 47 |
|
|
2018
Q3 | $1.05M | Buy |
13,612
+34
| +0.3% | +$2.51K | 0.6% | 55 |
|
|
2018
Q2 | $919K | Buy |
13,578
+525
| +4% | +$36.2K | 0.57% | 55 |
|
|
2018
Q1 | $946K | Buy |
13,053
+1,027
| +9% | +$78.2K | 0.6% | 55 |
|
|
2017
Q4 | $905K | Buy |
12,026
+869
| +8% | +$65.6K | 0.56% | 53 |
|
|
2017
Q3 | $858K | Buy |
11,157
+519
| +5% | +$39.2K | 0.58% | 54 |
|
|
2017
Q2 | $796K | Buy |
10,638
+62
| +0.6% | +$4.39K | 0.58% | 54 |
|
|
2017
Q1 | $704K | Buy |
10,576
+1,486
| +16% | +$99K | 0.54% | 54 |
|
|
2016
Q4 | $593K | Buy |
+9,090
| New | +$590K | 0.49% | 55 |
|
Other funds holding NVS
Perennial Advisors's NVS Position: Q2 2026 in Review
Perennial Advisors reduced its Novartis (NVS) stake by 52% in Q2 2026, selling an estimated $3.18M and leaving 19,702 shares worth $3.09M. The position accounts for 0.48% of the portfolio, ranked #60.
Perennial Advisors first reported a position in NVS in Q4 2016 and has held it in 38 quarters since. The position peaked at $6.25M in Q1 2026. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Perennial Advisors held 19,702 shares of Novartis worth $3.09M as of Q2 2026.
- Perennial Advisors sold 21,186 Novartis shares in Q2 2026, an estimated $3.18M.
- Novartis made up 0.48% of Perennial Advisors's portfolio in Q2 2026, its #60 holding.
- Perennial Advisors first reported a position in Novartis in Q4 2016 and has held it in 38 quarters since.
- Perennial Advisors's Novartis position peaked at $6.25M in Q1 2026.
- 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Perennial Advisors's 13F filing for Q2 2026, filed 13 Jul 2026.